Preprint · Mar 8, 2026
Digital Biomarkers Based on Wearable or Portable Devices for Identifying Prodromal Parkinson's disease: A Scoping Review
By Yu T
Parkinson's disease (PD) is a chronic neurodegenerative disorder commonly affecting middle-aged and elderly individuals, characterized by complex motor and non-motor symptoms. With the acceleration of population aging, PD has become one of the fastest-growing neurological disorders worldwide. By 2050, the global PD patient population is projected to reach 25.2 million—a 112% increase from 2021—with an age-standardized prevalence rate of 216 cases per 100,000 individuals, representing a 55% rise from 2021. In clinically diagnosed PD patients, irreversible progressive neuronal pathology has already occurred, with approximately 40%–50% loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). This leads to severe depletion of the neurotransmitter dopamine (DA) in striatal projection areas, reduced by about 80%–90%. Additionally, patients in the advanced stages of PD experience multidimensional functional decline and face increased risks of severe complications such as pneumonia and cardiovascular/cerebrovascular events, leading to a significant rise in mortality. Studies indicate that PD patients have a 33% to 61.7% higher all-cause mortality risk compared to the general population, with an average age at death of 71.65 ± 9.4 years—approximately 7 years shorter than China's current national life expectancy (78.6 years). However, traditional clinical diagnosis methods relying on motor symptoms have limitations. By the time of diagnosis, patients are often already in an irreversible pathological stage, missing the optimal window for intervention. Therefore, there is an urgent need to identify the disease during its prodromal stage. The prodromal stage of Parkinson's disease (pPD) refers to the presence of non-motor symptoms, or even mild motor symptoms, that do not yet meet the clinical diagnostic criteria for Parkinson's disease, but carry a very high risk of developing into PD within the next 10 years. The underlying molecular pathology during the pPD stage may still be reversible or at least more responsive to targeted interventions. Thus, identifying pPD individuals is crucial for enabling early intervention to delay or prevent PD onset. However, pPD symptoms are often subtle, difficult to monitor and observe, and some non-motor symptoms are frequently attributed to aging and consequently overlooked. Advancements in digital health technologies have revolutionized the measurement, collection, and storage of behavioral and physiological data in clinical settings. Algorithms transform acquired data into interpretable outcome metrics, giving rise to the novel concept of digital biomarkers. In recent years, digital biomarkers based on wearable or portable devices have gradually been applied to identify populations at risk for pPD. As research in this field remains in its early exploratory stages, studies exhibit significant heterogeneity and require systematic organization, analysis, and evaluation.